California Public Employees Retirement System Sells 158,734 Shares of Regeneron Pharmaceuticals, Inc. $REGN

California Public Employees Retirement System reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 33.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 314,716 shares of the biopharmaceutical company’s stock after selling 158,734 shares during the period. California Public Employees Retirement System owned approximately 0.30% of Regeneron Pharmaceuticals worth $165,226,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in REGN. Dodge & Cox increased its stake in Regeneron Pharmaceuticals by 64.6% in the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after acquiring an additional 1,502,198 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of Regeneron Pharmaceuticals by 1.6% during the 2nd quarter. Franklin Resources Inc. now owns 2,313,496 shares of the biopharmaceutical company’s stock valued at $1,214,585,000 after acquiring an additional 36,821 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Regeneron Pharmaceuticals by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock worth $1,379,467,000 after purchasing an additional 89,579 shares in the last quarter. Loomis Sayles & Co. L P grew its holdings in shares of Regeneron Pharmaceuticals by 18.6% during the second quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock worth $1,019,062,000 after purchasing an additional 305,089 shares in the last quarter. Finally, Amundi increased its position in shares of Regeneron Pharmaceuticals by 3.4% in the first quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company’s stock worth $979,794,000 after purchasing an additional 52,166 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $718.36 on Monday. The firm has a fifty day simple moving average of $650.69 and a two-hundred day simple moving average of $588.24. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $800.99. The company has a market capitalization of $75.50 billion, a PE ratio of 17.20, a P/E/G ratio of 2.06 and a beta of 0.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter in the previous year, the business earned $12.46 earnings per share. The company’s quarterly revenue was up .9% on a year-over-year basis. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were given a $0.88 dividend. The ex-dividend date was Thursday, November 20th. This represents a $3.52 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 8.43%.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Wells Fargo & Company boosted their price target on shares of Regeneron Pharmaceuticals from $615.00 to $700.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 20th. Rothschild & Co Redburn began coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a “buy” rating and a $890.00 price objective for the company. UBS Group upped their target price on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Raymond James Financial upgraded Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Finally, Guggenheim lifted their price target on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $777.36.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director owned 2,352 shares of the company’s stock, valued at $1,538,843.04. This represents a 73.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.